Efficacy of rapamycin in secondary prevention of skin cancers in kidney transplant recipients - multicentre randomized, open-label study of rapamycin vs calcineurin inhibitors.

Trial Profile

Efficacy of rapamycin in secondary prevention of skin cancers in kidney transplant recipients - multicentre randomized, open-label study of rapamycin vs calcineurin inhibitors.

Completed
Phase of Trial: Phase III

Latest Information Update: 21 May 2015

At a glance

  • Drugs Sirolimus (Primary) ; Ciclosporin; Tacrolimus
  • Indications Renal transplant rejection; Skin cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TUMORAPA; TUMORAPA-1
  • Most Recent Events

    • 26 Jul 2012 Primary endpoint 'Disease-occurrence-rate' has been met.
    • 26 Jul 2012 Primary endpoint 'Disease-free-survival-duration' has been met.
    • 16 Mar 2010 Actual patient number (77) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top